References
- Binetruy-Tournaire R, Demangel C, Malavaud B, et al. (2000). Identification of a peptide blocking vascular endothelial growth factor (VEGF)-mediated angiogenesis. Embo J 19:1525–33.
- Celia C, Trapasso E, Cosco D, et al. (2009). Turbiscan lab® expert analysis of the stability of ethosomes® and ultradeformable liposomes containing a bilayer fluidizing agent. Colloids Surf B: Biointerfaces 72:155–60.
- Chen ZJ, Zhai MF, Xie XY, et al. (2017). Apoferritin nanocage for brain targeted doxorubicin delivery. Mol Pharmaceutics 14:3087–97.
- Dolecek TA, Propp JM, Stroup NE, Kruchko C. (2012). Cbtrus Statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2005–2009. Neuro Oncol 14:v1–v49.
- Donahue MJ, Blakeley JO, Zhou J, et al. (2008). Evaluation of human brain tumor heterogeneity using multiple T1-based MRI signal weighting approaches. Magn Reson Med 59:336–44.
- Gao H. (2016). Progress and perspectives on targeting nanoparticles for brain drug delivery. Acta Pharm Sin B 6:268–86.
- Gao H. (2017). Perspectives on Dual Targeting Delivery Systems for Brain Tumors. J Neuroimmune Pharmacol 12:6–16.
- Gao H, Pang Z, Jiang X. (2013). Targeted delivery of nano-therapeutics for major disorders of the central nervous system. Pharm Res 30:2485–98.
- Goti D, Hrzenjak A, Levak-Frank S, et al. (2001). Porcine scavenger reeptor class B, type I is expressed at the blood-brain barrier and contributes to selective uptake of HDL associated vitamin E. J Neurochem 76:498–508.
- Guerrero-Cázares H, Tzeng SY, Young NP, et al. (2014). Biodegradable polymeric nanoparticles show high efficacy and specificity at DNA delivery to human glioblastoma in vitro and in vivo. ACS Nano 8:5141–53.
- Hu K, Li J, Shen Y, et al. (2009). Lactoferrin-conjugated PEG-PLA nanoparticles with improved brain delivery: in vitro and in vivo evaluations. J Control Release 134:55–61.
- Kader A, Pater A. (2002). Loading anticancer drugs into HDL as well as LDL has little affect on properties of complexes and enhances cytotoxicity to human carcinoma cells. J Control Release 80:29–44.
- Kang T, Jiang M, Jiang D, et al. (2015). Enhancing glioblastoma-specific penetration by functionalization of nanoparticles with an iron-mimic peptide targeting transferrin/transferrin receptor complex. Mol Pharm 12:2947–61.
- Khodarev NN, Yu J, Labay E, et al. (2003). Tumour-endothelium interactions in co-culture: coordinated changes of gene expression profiles and phenotypic properties of endothelial cells. J Cell Sci 116:1013–22.
- Kratzer I, Wernig K, Panzenboeck U, et al. (2007). Apolipoprotein A-I coating of protamine-oligonucleotide nanoparticles increases particle uptake and transcytosis in an in vitro model of the blood-brain barrier. J Control Release 117:301–11.
- Kreuter J. (2001). Nanoparticulate systems for brain delivery of drugs. Adv Drug Deliv Rev 47:65–81.
- Kuang Y, An S, Guo Y, et al. (2013). T7 peptide-functionalized nanoparticles utilizing RNA interference for glioma dual targeting. Int J Pharm 454:11–20.
- Kwan BCH, Kronenberg F, Beddhu S, Cheung AK. (2007). Lipoprotein metabolism and lipid management in chronic kidney disease. J Am Soc Nephrol 18:1246–61.
- Li XY, Zhao Y, Sun MG, et al. (2014). Multifunctional liposomes loaded with paclitaxel and artemether for treatment of invasive brain glioma. Biomaterials 35:5591–604.
- Lund-Katz S, Phillips MC. (2010). High Density Lipoprotein Structure-Function and Role in Reverse Cholesterol Transport. Subcell Biochem 51:183–227.
- Nativo P, Prior IA, Brust M. (2008). Uptake and Intracellular Fate of Surface-modified Gold Nanoparticles. ACS Nano 2:1639–44.
- Niu G, Chen X. (2010). Vascular endothelial growth factor as an anti-angiogenic target for cancer therapy. Curr Drug Targets 11:1000–17.
- Raymond AD, Diaz P, Chevelon S, et al. (2016). Microglia-derived HIV Nef+ exosome impairment of the blood-brain barrier is treatable by nanomedicine-based delivery of Nef peptides. J Neurovirol 22:129–39.
- Shaw TK, Mandal D, Dey G, et al. (2017). Successful delivery of docetaxel to rat brain using experimentally developed nanoliposome: a treatment strategy for brain tumor. Drug Deliv 24:346–57.
- Shinde RL, Devarajan PV. (2017). Docosahexaenoic acid-mediated, targeted and sustained brain delivery of curcumin microemulsion. Drug Deliv 24:152–61.
- Song QX, Song HH, Xu JR, et al. (2016). Biomimetic ApoE-Reconstituted High Density Lipoprotein Nanocarrier for Blood-Brain Barrier Penetration and Amyloid Beta-Targeting Drug Delivry. Mol Pharmaceutics 13:3976–87.
- Xie XY, Lin W, Liu H, et al. (2016). Ultrasound-responsive nanobubbles contained with peptide-camptothecin conjugates for targeted drug delivery. Drug Deliv 23:2756–64.
- Ying M, Zhan CY, Wang SL, et al. (2016). Liposome-based systemic glioma-targeted drug delivery enabled by all-dpeptides. ACS Appl Mater Interfaces 8:29977–85.
- Yuan Y, Wen J, Tang J, et al. (2016). Synthetic high-density lipoproteins for delivery of 10-hydroxycamptothecin. Int J Nanomedicine 11:6229–38.
- Zhang Y, Zhai MF, Chen ZJ, et al. (2017). Dual-modified liposome codelivery of doxorubicin and vincristine improve targeting and therapeutic efficacy of glioma. Drug Deliv 24:1045–55.
- Zhang H, Wu T, Yu W, et al. (2018). Ligand Size and Conformation Affect the Behavior of Nanoparticles Coated with in Vitro and in Vivo Protein Corona. ACS Appl Mater Interfaces 10:9094–103.
- Zhai MF, Wang YL, Zhang LG, et al. (2018). Glioma targeting peptide modified apoferritin nanocage. Drug Deliv 25:1013–24.
- Zhao ZX, Gao SY, Wang JC, et al. (2012). Self-assembly nanomicelles based on cationic mPEG-PLA-b-Polyarginine(R15) triblock copolymer for siRNA delivery. Biomaterials 33:6793–807.
- Zhu S, Qian L, Hong M, et al. (2011). RGD-modified PEG-PAMAM-DOX conjugate: in vitro and in vivo targeting to both tumor neovascular endothelial cells and tumor cells . Adv Mater Weinheim 23:H84–9.